Non-Cutaneous Melanoma — Trials

Non-Cutaneous Melanoma — Trials · CancerIndex

Clinical trials

Registered studies

312 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 87
Recruiting: 44
Ph III recruiting: 6
Growth YoY: —
Industry share: 28%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 36.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (45)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02506153	Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery	active not recruiting	Phase 3	1,301	National Cancer Institute (NCI)NIH	3	Aug 28, 2026	clinicaltrials
NCT06007690	A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma(CoMpass)	active not recruiting	Phase 3	108	Aura Biosciences